Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018 | ||
| By: Nasdaq / GlobeNewswire - 18 Oct 2018 | Back to overview list |
|
AMES, Iowa, Oct. 18, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results and to give an update on its clinical development activities. NewLink Genetics' senior management team will host the conference call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks. Access to the live conference call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/93n9r8pe. A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 1753698. About NewLink Genetics Corporation NewLink Genetics is a clinical stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit http://www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics. Investor & Media Contact: Lisa Miller |
||
|
||
 | Back to overview list | |